Management Ltd, London, UNITED KINGDOM; Ameren Services, St. Louis, MO; Anterix, Woodland Park, NJ; ATT Business, Dallas, TX; BEC Technologies, Richardson, TX; Blinq Network, Markham, CANADA; Bridgewater Group Consulting, Irvine, CA; Burns and McDonnell, Kansas City, MO; Cisco, San Jose, CA; Council Rock, Rochester, NY; CrescoNet, San Francisco, CA; Encore Networks, Chantilly, VA; Ericsson, Plano, TX; Evergy, Kansas City, MO; GE Industrial Communications, Rochester, NY; Hitachi-ABB, Raleigh, NC; JEA, Jacksonville, FL; K and A Engineering, White Plains, NY; L3 Harris, Rochester, NY; Mimomax Wireless, Christchurch, NEW ZEALAND; Motorola Solutions, Chicago, IL; Multi Tech Systems, Mounds View, MN; Nokia, Coppell, TX; NovaTech, Lenexa, KS; National Rural Telecommunications Cooperative, Herndon, VA; NY Power Authority (NYPA), White Plains, NY; Palmetto Technology Associates, Kiawah Island, SC; Puloli, Inc., San Francisco, CA; Southern California Edison, Rosemead, CA; SouthernLinc, Atlanta, GA; Telit Wireless Solutions, Durham, NC; World Wide Technology, Maryland Heights, MO; and Xcel Energy, Minneapolis, MN.

UBBA was formed as a Delaware nonstock member corporation. The general area of UBBA's planned activity is to empower utilities and ecosystem partners to champion the development of utility broad-band networks as a key enabler of the utility of the future, and to undertake such other activities as may from time to time be appropriate to further the purposes and achieve the goals set forth above.

Membership in UBBA remains open and UBBA intends to file additional written notifications disclosing all changes in membership.

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2021–12180 Filed 6–9–21; 8:45 am]

BILLING CODE 4410-11-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-847]

Importer of Controlled Substances Application: Cambrex Charles City

AGENCY: Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: Cambrex Charles City has applied to be registered as an importer

of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 12, 2021. Such persons may also file a written request for a hearing on the application on or before July 12, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 6, 2021, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616–3466, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Drug code	Schedule
8333	II
8501	II
9040	II
9600	II
9670	II
	8333 8501 9040 9600

The company plans to import the listed controlled substances for internal use and to bulk manufacture other controlled substances in Active Pharmaceutical Ingredient (API) form for distribution to its customers. No other activity for these drug codes is authorized for this registration.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2021–12215 Filed 6–9–21; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-844]

Importer of Controlled Substances Application: Fisher Clinical Services, Inc.

AGENCY: Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 12, 2021. Such persons may also file a written request for a hearing on the application on or before July 12, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 17, 2021, Fisher Clinical Services, Inc. 7554 Schantz Road, Allentown, Pennsylvania 18106–9032 applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana Extract	7350	1

The company plans to import the listed controlled substances for clinical trails only. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the